

February 25, 2010

Application Filed for Cancer Pain Drug (KW-2246)

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu, Saga; President: Hirotaka Nakatomi; hereinafter “Hisamitsu Pharmaceutical”) announced that as of February 24, 2010, Kyowa Hakko Kirin Co., Ltd. (hereinafter “Kyowa Hakko Kirin”) filed a new drug application for a cancer pain drug (KW-2246) which has been developed by Kyowa Hakko Kirin, and of which Hisamitsu Pharmaceutical obtained a joint distribution right in Japan from Kyowa Hakko Kirin in February 2010.

KW-2246 is a drug for the treatment of acute pain (breakthrough pain) during the management of sustained cancer pain that Kyowa Hakko Kirin has in-licensed from Orexo AB (Head Office: Uppsala, Sweden; CEO: Torbjörn Bjerke) with the expectations that the drug is rapidly absorbed and exerts an analgesic effect following sublingual administration.

KW-2246 will be jointly distributed by the two companies after Kyowa Hakko Kirin obtains its marketing authorization. Each company will individually distribute the product , and providing and collecting the information after launching into the market (1 brand through 2 channels).

Hisamitsu Pharmaceutical submitted a new drug application for a transdermal patch for the treatment of sustained cancer pain (development code: HFT-290) on June 26, 2008. With the addition of KW-2246, a drug for the treatment of breakthrough pain, to this, Hisamitsu Pharmaceutical wishes to contribute to improving the *Quality of Life* of patients who are suffering from cancer pain through comprehensive information provision.